<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12109">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02949297</url>
  </required_header>
  <id_info>
    <org_study_id>771-0013</org_study_id>
    <nct_id>NCT02949297</nct_id>
  </id_info>
  <brief_title>Expanding Patient Applicability With Polymer Sealing Ovation Alto Stent Graft IDE (Investigational Device Exemption) Study</brief_title>
  <acronym>ELEVATE</acronym>
  <official_title>Expanding Patient Applicability With Polymer Sealing Ovation Alto Stent Graft IDE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endologix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endologix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective clinical evaluation of the effectiveness of the Ovation Alto Abdominal Stent
      Graft System when used in the treatment of subjects with abdominal aortic aneurysm (AAA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective clinical evaluation of the effectiveness of the Ovation Alto Abdominal Stent
      Graft System when used in the treatment of subjects with abdominal aortic aneurysm (AAA).
      The primary objective is to evaluate treatment success at 12 months with the Ovation Alto
      Abdominal Stent Graft system. The study will have up to 15 sites, and up to 75 patients
      based on attrition rates. The follow-up intervals will be at 1, 6, and 12 months following
      initial implant procedure.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects with treatment success</measure>
    <time_frame>12 months</time_frame>
    <description>Treatment success is defined as technical success, freedom from type I and III endoleaks at 12 months, freedom from stent graft migration &gt; 10m at 12 months compared to 1 month baseline, freedom from AAA enlargement &gt;5mm at 12 months (compared to 1-month baseline, freedom from AAA rupture through 12 months, freedom from conversion to open repair through 12 months, stent graft stenosis, occlusion or kink requiring secondary intervention through 12 months, thromboembolic event attributable to stent graft requiring secondary intervention through 12 months, stent fracture requiring secondary intervention through 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Classification of Endoleaks</measure>
    <time_frame>1, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Graft Migration &gt; 10mm</measure>
    <time_frame>1, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AAA enlargement &gt; 5mm</measure>
    <time_frame>1, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AAA rupture</measure>
    <time_frame>1, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion to open repair</measure>
    <time_frame>1, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Secondary Interventions</measure>
    <time_frame>1, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AAA-related mortality</measure>
    <time_frame>1, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-related Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>1, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>1, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of patency</measure>
    <time_frame>1, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent fracture</measure>
    <time_frame>1, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic event</measure>
    <time_frame>1, 6, and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Aortic Aneurysm, Abdominal</condition>
  <arm_group>
    <arm_group_label>Ovation Alto Abdominal Stent Graft System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Endovascular repair of AAA using the Ovation Alto Abdominal Stent Graft System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ovation Alto Abdominal Stent Graft System</intervention_name>
    <description>Repair of Abdominal Aortic Aneurysm with Ovation Alto Abdominal Stent Graft System</description>
    <arm_group_label>Ovation Alto Abdominal Stent Graft System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:

          1. Patient has adequate iliac/femoral access compatible with the required delivery
             systems.

          2. Patient has non-aneurysmal proximal aortic neck.

          3. Patient has non-aneurysmal distal iliac landing zone.

        Exclusion Criteria include:

          1. Patient has dissecting aneurysm.

          2. Patient has acutely ruptured aneurysm.

          3. Patient has need for emergent surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Lyden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noel L Smith, BS</last_name>
    <phone>707-543-8696</phone>
    <email>nsmith@endologix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen Huhn</last_name>
    <phone>707-543-8625</phone>
    <email>khuhn@endologix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sean Lyden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.endologix.com</url>
    <description>Endologix Website</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>October 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>abdominal</keyword>
  <keyword>aortic</keyword>
  <keyword>aneurysm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
